このアイテムのアクセス数: 177

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
29_1147.pdf1.5 MBAdobe PDF見る/開く
タイトル: 緑膿菌による慢性複雑性尿路感染症に対するCefpiramide(SM-1652)とCefsulodinの二重盲険法による臨床効果の比較
その他のタイトル: Double-blind comparative clinical study of cefpiramide (SM-1652) and cefsulodin on complicated urinary tract infections due to P. aeruginosa
著者: 河村, 信夫  KAKEN_name
大越, 正秋  KAKEN_name
岡田, 敬司  KAKEN_name
熊本, 悦明  KAKEN_name
宮本, 慎一  KAKEN_name
新島, 端夫  KAKEN_name
岸, 洋一  KAKEN_name
西村, 洋司  KAKEN_name
斉藤, 功  KAKEN_name
弓削, 順二  KAKEN_name
塚田, 修  KAKEN_name
町田, 豊平  KAKEN_name
小野寺, 昭一  KAKEN_name
清田, 浩  KAKEN_name
斎藤, 豊一  KAKEN_name
三橋, 慎一  KAKEN_name
木村, 哲  KAKEN_name
鈴木, 恵三  KAKEN_name
西浦, 常雄  KAKEN_name
河田, 幸道  KAKEN_name
長谷川, 義和  KAKEN_name
波多野, 紘一  KAKEN_name
磯貝, 和俊  KAKEN_name
堀江, 正宣  KAKEN_name
鄭, 漢彬  KAKEN_name
嶋津, 良一  KAKEN_name
名出, 頼男  KAKEN_name
長久保, 一朗  KAKEN_name
置塩, 則彦  KAKEN_name
大川, 光央  KAKEN_name
久住, 治男  KAKEN_name
平野, 章治  KAKEN_name
美川, 郁夫  KAKEN_name
南後, 千秋  KAKEN_name
石神, 襄次  KAKEN_name
守殿, 貞夫  KAKEN_name
荒川, 創一  KAKEN_name
畑地, 康助  KAKEN_name
中野, 博  KAKEN_name
仁平, 寛巳  KAKEN_name
藤井, 元広  KAKEN_name
平山, 多秋  KAKEN_name
林, 睦雄  KAKEN_name
米田, 健二  KAKEN_name
室本, 哲男  KAKEN_name
松木, 暁  KAKEN_name
相模, 浩二  KAKEN_name
白石, 恒雄  KAKEN_name
赤沢, 信幸  KAKEN_name
大森, 弘之  KAKEN_name
難波, 克一  KAKEN_name
近藤, 淳  KAKEN_name
赤枝, 輝明  KAKEN_name
黒川, 一男  KAKEN_name
藤村, 宣夫  KAKEN_name
湯浅, 健司  KAKEN_name
小倉, 邦博  KAKEN_name
淡河, 洋一  KAKEN_name
植田, 省吾  KAKEN_name
江藤, 耕作  KAKEN_name
宮原, 茂  KAKEN_name
岡本, 健一郎  KAKEN_name
大井, 忠好  KAKEN_name
川畠, 尚志  KAKEN_name
小畠, 道夫  KAKEN_name
島田, 剛  KAKEN_name
白浜, 勉  KAKEN_name
陳, 英輝  KAKEN_name
田中, 恒男  KAKEN_name
出口, 浩一  KAKEN_name
著者名の別形: Kawamura, Nobuo
Ohkoshi, Masaaki
Okada, Keishi
Kumamoto, Yoshiaki
Miyamoto, Shinichi
Niijima, Tadao
Kishi, Yoichi
Nishimura, Yoji
Saito, Isao
Yuge, Junji
Tsukada, Osamu
Machida, Toyohei
Onodera, Shoichi
Kiyota, Hiroshi
Saito, Toyokazu
Mitsuhashi, Shinichi
Kimura, Satoru
Suzuki, Keizo
Nishiura, Tsuneo
Kawada, Yukimichi
Hasegawa, Yoshikazu
Hatano, Koichi
Isogai, Kazutoshi
Horie, Masanobu
Tei, Kanri
Shimazu, Ryoichi
Naide, Yorio
Nagakubo, Ichiro
Okishio, Norihiko
Ohkawa, Mitsuo
Hisazumi, Haruo
Hirano, Shoji
Mikawa, Ikuo
Nango, Chiaki
Ishigami, Joji
Kamidono, Sadao
Arakawa, Soichi
Hatachi, Kosuke
Nakano, Hiroshi
Nihira, Hiromi
Fujii, Motohiro
Hirayama, Masaaki
Hayashi, Mutsuo
Yoneda, Kenji
Muromoto, Tetsuo
Matsuki, Akira
Sagami, Koji
Shiraishi, Tsuneo
Akazawa, Nobuyuki
Ohmori, Hiroyuki
Nanba, Katsuichi
Kondo, Atsushi
Akaeda, Teruaki
Kurokawa, Kazuo
Fujimura, Nobuo
Yuasa, Kenji
Ogura, Kunihiro
Aga, Yoichi
Ueda, Shogo
Eto, Kosaku
Miyahara, Shigeru
Okamoto, Kenichiro
Ohi, Yoshitada
Kawabata, Takashi
Obata, Michio
Shimada, Takeshi
Shirahama, Tsutomu
Chan, Ying Fai
Tanaka, Tsuneo
Deguchi, Koichi
キーワード: Adult
Aged
Cefsulodin
Cephalosporins/administration & dosage/adverse effects/therapeutic use
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Injections, Intravenous
Male
Middle Aged
Pseudomonas Infections/drug therapy
Urinary Tract Infections/drug therapy/microbiology
発行日: Sep-1983
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 29
号: 9
開始ページ: 1147
終了ページ: 1188
抄録: P. aeruginosaによる複雑性尿路感染症に対するCPMの治療効果と副作用を評価する目的で,CPM 2g/日とCFS 2g/日の二重盲検法による比較試験をおこなった.総投与例数は274例で,うち効果を判定し得たのはCPM群136例,CFS群118例であった.1) P. aeruginosaを含む感染症では,CPMあるいはCFSを1日2g,5日間投与時の効果では,前者の有効率が有意に高かった.2) P. aeruginosaのみを対象にした場合も同様であった.3) P. aeruginosaを含む感染で細菌尿の陰性化率はCPM群はCFS群より有意に高かった.4)交代菌の出現は,CFS群でS. faecalisの出現率が有意に高く,全体的にもCFS群の投与後の細菌出現率が有意に高かった,5)薬剤投与開始前の分離菌のMICでは,CPM群の方がCFS群よりもMICの低いものが多かった.6)副作用発現率,臨床検査値の異常化は両群間に差はなかった
The therapeutic efficacy and safety of Cefpiramide (CPM, SM-1652) at a 2 g/day dose were objectively compared with those of Cefsulodin (CFS) at a 2 g/day dose in patients with chronic complicated urinary tract infections (UTI) by P. aeruginosa in a double-blind study at 46 institutions in Japan. The results are as follows: The therapeutic efficacy was analyzed in 254 patients (136 cases administered CPM and 118 cases administered CFS) after excluding 20 cases as drop-out. Among 254 cases, the number of patients with infection of P. aeruginosa was 190 cases (100 cases administered CPM and 90 cases administered CFS), while that with infection of organisms other than P. aeruginosa was 64 cases (36 cases administered CPM and 28 cases administered CFS). By the administration of a 2 g/day dose for 5 days, the overall clinical effective rate of CPM was significantly higher than that of CFS in total patients. When the patients were classified into 2 groups with respect to causative organisms (P. aeruginosa and others), the clinical effective rate of CPM in patients with infections of P. aeruginosa was significantly higher than that of CFS, while the clinical effective rate of CPM in patients with infection of other organisms than P. aeruginosa was the same as that of CFS. As to the bacteriological effect on bacteriuria, the eradication rate of CPM was significantly higher than that of CFS not only against all causative organisms but also against P. aeruginosa. The rate of replacement by S. faecalis was significantly higher in the CFS-treated group than in the CPM-treated group. The same result was obtained on the rate of replacement by other organisms. The MIC values of CPM for isolated organisms before drug administration were lower than those of CFS. The incidence rates of side effects and the abnormal findings of clinical laboratory tests were the same for the CPM- and CFS-treated groups. From the results, it was concluded that CPM is a useful drug for the treatment of patients with chronic complicated urinary tract infections caused by P. aeruginosa.
URI: http://hdl.handle.net/2433/120233
PubMed ID: 6375316
出現コレクション:Vol.29 No.9

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。